Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the Danish drugmaker to cut its ...

BofA analysts expect Novo Nordisk's first-quarter sales to reach 77 billion Danish kroner (DKK), a 17% year-over-year increase, and earnings before interest and taxes (EBIT) to hit DKK 36 billion ...

GDANSK/LONDON, March 28 (Reuters) - Bank of America analysts on Friday said Novo Nordisk (NOVOb.CO), opens new tab may miss first-quarter expectations, as sales of its blockbuster Wegovy and ...